Declaration of competing financial interests
From the following article:
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Scott M. Grundy
Nature Reviews Drug Discovery 5, 295-309 (April 2006)
doi:10.1038/nrd2005
Declaration: During the past 5 years, S.M.G. has been an investigator on research grants awarded to the University of Texas Southwestern Medical Center, Dallas, Texas, USA, from Merck, Abbott and Kos Pharmaceuticals. He has also served as a consultant for Merck, Merck Schering Plough, Kos, Abbott, Fournier, Bristol-Myers Squibb, Sankyo, AstraZeneca and Sanofi-Aventis.
